Skip to main content
. 2020 Oct 15;10(4):455–462.

Table 3.

Clinical progress & outcomes

All (n=613) Caucasian (n=292) Asian (n=203) Afro-Caribbean (n=118) Adjusted OR/HR Adjusted OR/HR
95% CI 95% CI
Asians* Afro-Caribbean*
Chest pain 17.5% (63) 12.7% (24) 19.8% (24) 31.9% (15) 1.60 2.09
0.86-2.98 1.06-4.09
Myocardial Infarction 3.1% (19) 3.1% (9) 3.0% (6) 3.4% (4) 0.76 0.92
0.21-2.80 0.22-3.93
Myocardial Injury** 66.1% (287) 72.1% (137) 56.3% (90) 71.4% (60) 1.12 2.64
0.55-2.26 1.10-6.35
Acute HF 7.2% (44) 5.1% (15) 6.9% (14) 12.7% (15) 1.72 3.64
0.71-4.15 1.50-8.84
Ischaemic Stroke 2.4% (15) 2.1% (6) 2.5% (5) 3.4% (4) 0.81 0.66
0.26-2.56 0.16-2.77
AF episode 7.3% (45) 9.9% (29) 6.4% (13) 2.5% (3) 0.55 0.25
0.24-1.30 0.07-0.90
Ventricular Tachycardia 0.3% (2) 0% (0) 1.0% (2) 0% (0) N/A N/A
Venous Thromboembolic disease 5.5% (34) 3.8% (11) 8.4% (17) 5.1% (6) 4.10 1.77
1.49-11.27 0.52-6.07
Death During Admission 33.4% (201) 33.2% (97) 32.7% (65) 35.1% (39) 1.89 2.03
1.24-2.90 1.28-3.23
Pneumonia 75.4% (460) 69.8% (20) 82.3% (167) 77.6% (90) 1.90 1.41
1.10-3.31 0.77-2.59
Acute Kidney Injury 36.3% (218) 37.4% (108) 31.6% (62) 41.4% (48) 0.87 2.11
0.51-1.49 1.15-3.86

Abbreviations: HF: heart failure;

*

Caucasian Ethnicity used as reference & OR used for all comparisons, except for survival;

**

High sensitivity troponin ≥15 ng/L, the 99th percentile of normal;

Note: Adjustment performed for: age, hypertension, type-2 diabetes mellitus, eGFR, BMI, and use of NSAIDs and Immunosupression prior to admission.